Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;180(3):959-966.
doi: 10.1007/s00431-020-03811-4. Epub 2020 Oct 13.

Lymphatic malformations in children: treatment outcomes of sclerotherapy in a large cohort

Frédérique C M Bouwman  1   2   3 , Silje S Kooijman  4 , Bas H Verhoeven  4   5 , Leo J Schultze Kool  6   5 , Carine J M van der Vleuten  7   5 , Sanne M B I Botden  4   5 , Ivo de Blaauw  4
Affiliations

Lymphatic malformations in children: treatment outcomes of sclerotherapy in a large cohort

Frédérique C M Bouwman et al. Eur J Pediatr. 2021 Mar.

Abstract

This retrospective study examines the outcomes of sclerotherapy in children with (veno)lymphatic malformations who received sclerotherapy between 2011 and 2016 (116 children, 234 procedures). Complication severity was classified using the Society of Interventional Radiology classification. Clinical response was rated on a scale of 0 (no change) to 3 (good improvement). The sclerosants used were bleomycin (n = 132; 56%), lauromacrogol (n = 42; 18%), doxycycline (n = 15; 6%), ethanol (n = 12; 5%), or a combination (n = 33; 14%). Four major and 25 minor complications occurred without significant differences between the agents. The median response rate per procedure was 2-some improvement-for all sclerosants. However, in pure LMs (67%), bleomycin and a combination of agents resulted in the best clinical response. On patient level, all had some or good clinical response. Mixed macrocystic and microcystic lesions showed a significantly lower clinical response (median 2 versus 3; p = 0.023 and p = 0.036, respectively) and required significantly more procedures (median 2 versus 1; p = 0.043 and p = 0.044, respectively) compared with lesions with one component.Conclusion: Sclerotherapy for (V)LMs in children is safe and effective. Bleomycin is the most frequently used agent in this clinic and seemed most effective for pure LMs. Mixed macrocystic and microcystic lesions are most difficult to treat effectively. What is Known: • A variety of agents can be used for sclerotherapy of lymphatic malformations in children. • Macrocystic lesions have favorable outcomes compared with microcystic and mixed lesions. What is New: • Bleomycin and a combination of agents seem to be most effective to treat lymphatic malformations in children. • Mixed macrocystic and microcystic lesions are more difficult to treat effectively compared with lesions with either one of these components.

Keywords: Bleomycin; Lauromacrogol; Lymphatic malformation; Sclerotherapy; Vascular malformation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Mulliken JB, Burrows PE, Fishman S.J. (2013) Mulliken and Young’s vascular anomalies: hemangiomas and malformations.562-594
    1. Defnet AM, Bagrodia N, Hernandez SL, Gwilliam N, Kandel JJ. Pediatric lymphatic malformations: evolving understanding and therapeutic options. Pediatr Surg Int. 2016;32(5):425–433. doi: 10.1007/s00383-016-3867-4. - DOI - PubMed
    1. Manning SC, Perkins J. Lymphatic malformations. Curr Opin Otolaryngol Head Neck Surg. 2013;21(6):571–575. doi: 10.1097/MOO.0000000000000007. - DOI - PubMed
    1. Acevedo JL, Shah RK, Brietzke SE. Nonsurgical therapies for lymphangiomas: a systematic review. Otolaryngol Head Neck Surg. 2008;138(4):418–424. doi: 10.1016/j.otohns.2007.11.018. - DOI - PubMed
    1. Shergill A, John P, Amaral JG. Doxycycline sclerotherapy in children with lymphatic malformations: outcomes, complications and clinical efficacy. Pediatr Radiol. 2012;42(9):1080–1088. doi: 10.1007/s00247-012-2406-2. - DOI - PubMed

Substances

LinkOut - more resources